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Background: There is no specific quality of life (QoL) measurement tool to quantify QoL in patients with biliary tract cancer.
Quality of life measurement is an increasingly crucial trial end point and is now being incorporated into clinical practice.
Methods: This International Multicentre Phase IV Validation Study assessed the QLQ-BIL21 module in 172 patients with
cholangiocarcinoma and 91 patients with cancer of the gallbladder. Patients completed the questionnaire at baseline pretherapy
and subsequently at 2 months. Following this, the psychometric properties of reliability, validity, scale structure and
responsiveness to change were analysed.
Results: Analysis of the QLQ-BIL21 scales showed appropriate reliability with Cronbach’s a-coefficients40.70 for all scales overall.
Intraclass correlations exceeded 0.80 for all scales. Convergent validity 40.40 was demonstrated for all items within scales, and
discriminant validity was confirmed with valueso0.70 for all scales compared with each other. Scale scores changed in accordance
with Karnofsky performance status and in response to clinical change.
Conclusions: The QLQ-BIL21 is a valid tool for the assessment of QoL in patients with cholangiocarcinoma and cancer of the
gallbladder.
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Malignant diseases of the biliary tree, encompassing cholangio-
carcinoma and cancer of the gallbladder, are relatively rare, with
evidence that incidence is rising (McGlynn et al, 2006). Incidence
in the United States has been reported as between 1 and 2.5 cases
per 100 000 per year (Kaushik, 2001; Khan et al, 2005), although
rates of up to 96 per 100 000 have been reported in some high-risk
populations (Shaib and El-Serag, 2004).
To date, cholangiocarcinoma and cancer of the gallbladder are
associated with poor outcomes and impaired quality of life (QoL)
(Heffernan et al, 2002). Patients presenting with advanced disease
may have a mean survival of p12 months (Anderson et al, 2004).
Extrahepatic disease has a marginally better prognosis than
intrahepatic disease (Ahmed et al, 2008).
Presenting symptoms in cholangiocarcinoma are dependent on
the location of the malignancy in the biliary tree (Anderson et al,
2004) and are directly related to obstruction of the biliary tree
(DeOliveira et al, 2007). Intrahepatic disease may manifest as a
liver mass or cholangitis with possible intrahepatic abscess
formation as well as right upper quadrant pain related to capsular
distension, whereas extrahepatic neoplasms lead to painless
obstructive jaundice and cholangitis. Gallbladder cancer may be
found incidentally at cholecystectomy; however, it may present
with pain due to mass effects and may also trigger obstructive
jaundice. In addition to local effects, systemic symptoms such as
weight loss, fevers and anorexia are commonly seen.
Treatments consist of surgical resection (DeOliveira et al, 2007),
biliary stenting or external drainage (Patel and Singh, 2007),
chemotherapy (Hong et al, 2007) and radiotherapy (Ben-David
et al, 2006). Significant survival benefits have not been reliably
demonstrated (Malhi and Gores, 2006; Hong et al, 2007) and
treatment-related QoL changes are poorly studied.
Quality of life and its measurements are increasingly regarded as
crucial end points in clinical trials, as well as being gradually
introduced into day-to-day clinical practice. There is paucity of
data regarding QoL in cholangiocarcinoma and cancer of the
gallbladder, and to date there is no disease-specific questionnaire
available. The need for a disease-specific QoL questionnaire, and its
subsequent development from phase I to III was first reported in
2011 (Friend et al, 2011). The European Organization for Research
and Treatment of Cancer (EORTC) QLQ-BIL21 (Supplementary
material) is a new disease-specific module to be used with the
existing generic EORTC QLQ-C30 tool (Aaronson et al, 1993).
This study describes an International Phase IV Psychometric
Validation Study designed to assess the clinical and psychometric
reliability, validity and responsiveness to change of the QLQ-BIL21
questionnaire in patients with cholangiocarcinoma and cancer of
the gallbladder.
MATERIALS AND METHODS
The EORTC guidelines (Blazeby et al, 2002) for module
development were followed in this international multicentre study.
The initial phases involve a process of collating a list of issues from
patients, health-care workers and previous publications, which are
subsequently developed into a bank of questions from which
the module is constructed. The module is then tested in a Phase IV
Validation Study.
Questionnaires. This study required patients to complete two
paper questionnaires at all assessment time points: the well-
established EORTC generic cancer questionnaires QLQ-C30 and
the QLQ-BIL21. The QLQ-BIL21 consists of 21 questions: 3 single-
item assessments relating to treatment side effects, difficulties with
drainage bags/tubes and concerns regarding weight loss, in
addition to 18 items grouped into 5 proposed scales: eating
symptoms (4 items), jaundice symptoms (3 items), tiredness
(3 items), pain symptoms (4 items) and anxiety symptoms
(4 items). The response format was a four-point Likert scale.
Responses to the QLQ-C30 and QLQ-BIL21 questionnaires
were transformed into a 0–100 scale using EORTC guidelines.
Translations according to EORTC guidelines (Dewolf et al, 2009)
were completed for six languages (German, Dutch, Italian, Spanish,
Mandarin Chinese and Hindi).
Recruitment. Patients were recruited between September 2011 and
June 2014, and were eligible for inclusion if they were aged 18 years
or above, with a diagnosis of cholangiocarcinoma or gallbladder
cancer confirmed by histology or MDT (multidisciplinary team)
opinion, were able to give written informed consent, had no prior
history of other significant malignant disease, were able to under-
stand the language of the questionnaire and had an expected
minimum survival of 3 months. Patients were excluded if there was
concurrent malignant disease elsewhere (except basal cell carcinoma
of the skin), if prior surgery with curative intent had taken place
(with no evidence of recurrence), or if psychological, familial,
sociological or geographical reasons would hamper compliance with
the study protocol. Ethics committee approval and individual written
patient consent was obtained. The study protocol was approved by
the EORTC QoL group.
Study design. QoL changes may be different following major
surgical interventions when compared with procedural therapies or
compared with supportive care alone; thus, patients were assigned
to one of three groups depending on their planned treatment:
Intervention Group 1 (surgical treatment including prior stents or
drains), Intervention Group 2 (chemotherapy/radiotherapy/photo-
dynamic therapy/laser therapy including prior stents or drains)
and Intervention Group 3 (supportive care only, but not excluding
stents or drains). Prior active treatment was not a barrier to
participation provided all residual effects of the intervention had
resolved by the time the patient was enrolled.
Patients completed both questionnaires (QLQ-C30 with QLQ-
BIL21) at baseline. This was within 1 month before commencing
treatment for Intervention Groups 1 and 2; for Intervention Group 3,
the baseline assessment was performed as soon as the decision to
proceed with supportive care had been made, and all patients
completed a second set 2 months post baseline within a 2-week
window. The Karnofsky performance status (KPS) was recorded at
both time points. All patients completed a short paper debriefing
questionnaire following the baseline assessment, covering issues
such as completion time or identifying questions that were
confusing, upsetting or difficult to answer.
Test–retest reliability was assessed in 67 clinically stable patients
from across all three intervention groups 2 weeks after the
2-month follow-up assessment. Patients receiving intravenous
chemotherapy at the time were excluded from participating in the
test–retest element.
Statistical analysis
Reliability. The reliability, or internal consistency, of the QLQ-
C30 and QLQ-BIL21 questionnaires was assessed by Cronbach’s
a-coefficient (Cronbach and Warrington, 1951). An internal
consistency estimate of 40.70 was considered acceptable for
group comparison (Nunnally, 1994). Test–retest reliability was
measured by calculating intraclass correlations (ICCs) for the
QLQ-C30 and QLQ-BIL21 questionnaires. An ICC of 40.90 is
considered desirable, but values as low as 0.70 are acceptable for
clinical use.
Validity. Multitrait scaling was used to examine the hypothesised
scale structure of the individual items of the QLQ-BIL21. To test
item scale convergence validity, a correlation of X0.40 was used.
Comparison of an item with its own scale as compared with other
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scales was used to support item-discriminant validity (Hays et al,
1988). Items were expected to correlate significantly better (at least
twice the standard error) with its own scale than with other scales.
Three distinct approaches were used to evaluate the validity of
the QLQ-BIl21:
(i) Convergent validity of the QLQ-C30 and QLQ-BIL21 ques-
tionnaires: This was examined using Pearson’s product–
moment correlation. It was expected that conceptually related
scales will correlate substantially with each other (Pearson’s
r40.40), and conversely scales that are less related will exhibit
lower correlations (Pearson’s ro0.40).
(ii) Known group comparison of the QLQ-C30 and QLQ-BIL21
questionnaires: This was performed to explore the ability of
the questionnaire to discriminate between subgroups of
patients differing in their clinical status, such as site
(gallbladder vs intrahepatic cholangiocarcinoma vs extrahe-
patic cholangiocarcinoma vs disseminated disease) or treat-
ment (resection possible vs inoperable). Differences were
assessed using the T-test and if any were close to being
nonsignificant, and were checked using Wilcoxon’s rank sum
for nonparametric data.
(iii) Responsiveness to clinical change over time of the QLQ-C30
and QLQ-BIL21 questionnaires: This was assessed using the
two sets of questionnaires available for each patient over time,
with the mean QoL scores over time for items and scales
reflecting change in QoL, the development of disease
recurrence or metastases and performance status. These
changes were compared by repeated-measure analysis of
variance (ANOVA).
Statistical Package for the Social Science (SPSS) software (IBM
Corporation, Armonk, NY, USA) was used for data analysis and the
linear transformation of responses to the QLQ-C30 and QLQ-BIL21
questionnaires to a 0–100 scale using EORTC guidelines and SPSS
syntax. Stata 11 was used for all analyses and a P-value of 0.01 was
deemed significant. The method outlined in the EORTC scoring
manual was used to impute missing data points (Fayers) http://
groups.eortc.be/qol/manuals.
Sample size. The sample size was calculated to be 231 patients
(Walter et al, 1998) based on the anticipation of a 5% attrition rate
from enrolment to completion, and taking into account that a
sample of 220 patients is required to achieve 80% power to detect
differences in the a-coefficient under a null hypothesis of 0.60 and
the alternative hypothesis of 0.70 using a two-sided F-test with a
significance level of 0.05. A minimum sample of 210 is needed to
achieve 10 responses per item (Tabachnik, 1993).
RESULTS
Enrolment. A total of 172 patients with cholangiocarcinoma and
91 patients with cancer of the gallbladder were recruited making a
total of 263 eligible patients. Eleven centres in the United Kingdom
(143 patients recruited overall), 2 in Germany (13 patients
recruited overall) and 1 each in the Netherlands (14 patients),
Italy (12 patients), Chile (4 patients), India (42 patients) and China
(7 patients) enrolled a total of 263 patients fulfilling the study’s
inclusion criteria. Intervention Group 1 consisted of 44 patients
receiving surgical treatments (16.9%), and Intervention Group 2
consisted of 103 patients receiving medical treatments (39.6%).
Patients in the Intervention Group 3 (113 patients or 43.4%)
received supportive care (no interventions with the exception of
drains or stents). Three of the 263 patients were not attributed to a
treatment group. Overall, 98 patients or 37.1% received a stent and
drainage was performed in 31 or 11.7% of patients
Questionnaire completion. In total, 478 questionnaires were
available for analysis. Of the 263 patients enrolled, 75 were not
able to complete the study at 2 months (48 died, 11 were lost to
follow-up, 13 too unwell and 3 for other reasons). Notably, 62%
(n¼ 30) of patients who died were enrolled in India, representing
70% of all Indian patients.
Debriefing results. Of the 263 patients in the study, 256
completed the debriefing questionnaire at the baseline assessment.
Of these, 66% (n¼ 168) did so in the hospital outpatient clinic,
10.9% at home (n¼ 28), 7.8% (n¼ 20) as an in-patient and 15.2%
(n¼ 39) elsewhere. Overall, 89.1% of patients completed both
QLQ-C30 and QLQ-BIL21 questionnaires ino20min, with 38.3%
patients (n¼ 98) completing in o10min, 34.4% in 11–15min
(n¼ 88), 16.4% in 16–20min (n¼ 42), 9% in 21–30min (n¼ 23)
and 1.6% taking over 30min (n¼ 4). Help completing the
questionnaire from family members or health-care staff was
necessary in 46.4% of patients. A total of 41 patients (16%)
found one or more items confusing or difficult to answer, the
most common of which were question 49 (found confusing by
10 patients) and question 50 (found confusing by 4 patients) in the
QLQ-BIL21 questionnaire. Forty-five per cent of patients (n¼ 115)
found at least one question not relevant. In the QLQ-BIL21
questionnaire, question 50 (pertaining to drainage tubes and bags)
was considered irrelevant by 29 patients. Question 49 was deemed
irrelevant by 16 patients, and in the QLQ-BIL21 questionnaire,
questions 37 and 35 (both pertaining to jaundice) were deemed
irrelevant by 12 and 10 patients, respectively.
QLQ-BIL21 scale structure: consistency and reliability. The
internal consistency of the QLQ-C30 and QLQ-BIL21 question-
naires was calculated for each scale at baseline, at 2-month follow-
up and as an overall global score (Table 1). The overall global score
of Cronabach’s a coefficients was calculated using all data
including at baseline as well as at 2 months. Cronbach’s a-
coefficients for all scales in the QLQ-BIL21 questionnaire exceeded
the threshold of 0.70 at baseline (ranges 0.71–0.87). Overall
Cronbach’s a-coefficients for the QLQ-BIL21 scales all met the 0.70
threshold (ranges 0.71–0.89). For the QLQ-C30 questionnaire, a
Cronbach’s a-coefficient of 40.70 was met for all scales except
Physical Function (a¼ 0.47), Cognitive Function (a¼ 0.65) and
Nausea/Vomiting (a¼ 0.67) at baseline.
Intraclass correlations (Table 2) were calculated using the
67 individuals in the study who completed the test–retest
questionnaire 2 weeks following the second assessment. ICC
values for the QLQ-C30 scales varied from 0.52 to 0.92. All scales
in the QLQ-BIL21 scale scored ICC values 40.8, the only ones
scoringp0.9 being the Eating (ICC¼ 0.87), Jaundice (ICC¼ 0.86),
Treatment Side effects (ICC¼ 0.83) and Weight Loss (ICC¼ 0.81).
No ICC value in the QLQ-BIL21 scale fell below 0.80, well above
the acceptable value of 40.70 (Fayers, 2000).
Construct validity. Construct validity was determined for all
scales using convergent and discriminant validity. Convergent
validity was calculated for each scale in both the QLQ-C30 and
QLQ-BIL21 questionnaires. For both questionnaires, all items
had Pearson’s r correlations 40.4 for their own scales (Table 3).
Table 1. Cronbach’s a for BIL21 scales
Cronbach’s a Cronbach’s a Cronbach’s a
Scale Baseline 2 months Overall
BIL21
Eating 0.75 0.77 0.75
Jaundice 0.71 0.61 0.71
Tiredness 0.87 0.93 0.89
Pain 0.81 0.68 0.78
Anxiety 0.8 0.8 0.81
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This confirms the clinical reasoning that the individual questions
have been placed in the correct scales and are broadly measuring
aspects of the same theme. Discriminant validity was calculated for
all items in the QLQ-BIL21 questionnaire, none of which were
40.70. This indicates that none of the items correlate with scales
outside the scale they have been placed into and indicated that
items must therefore be in the correct scale.
Clinical validity. The ability of the QLQ-BIL21 questionnaire to
correlate with clinical scores of function at discrete time points was
assessed using KPS scores at baseline stratified into two groups
(KPS o70 and 470). The difference in scores for each scale in
these two groups subsequently underwent group comparison
testing (n¼ 238–256; Table 4). This shows that the QLQ-BIL21
questionnaire is able to identify significant differences in mean
scale scores between the two Karnofsky groups in all scales except
Jaundice (P¼ 0.139) and Weight loss (P¼ 0.898). This may be
explained by the fact that weight loss is a less prominent feature in
biliary malignancies than in other GI cancers. The lack of
correlation between jaundice and low KPS is of particular interest.
Responsiveness to clinical change over time. Clinical change
over time was assessed by comparing mean scale scores at baseline
and follow-up in 154–178 patients (this variation was due to some
scales not being fully completed at the follow-up assessment)
(Table 5). Changes in mean scores by scale over time are a measure
of clinical responsiveness. These changes were only significant
for eating, jaundice, tiredness, pain and treatment side effects.
A change in mean scale score of 410% was only seen in the
treatment side effects item (D12.54). Changes over the 2-month
follow-up period for anxiety (P¼ 0.066), drains (P¼ 0.834) and
weight loss (P¼ 0.519) were not significant.
Analysis of the changes to scales over time stratified by the
intervention group (Table 5) showed more subtle changes. Eating
symptoms changed minimally by a nonsignificant margin in all
three intervention groups. Jaundice symptoms showed a modest
improvement (change of  13.7) in the Intervention Group 1
(surgery), with a smaller change ( 5.6) in the Intervention
Group 2 (medical therapies including chemotherapy and radio-
therapy). There were no significant changes to jaundice symptoms
in the Intervention Group 3 (supportive care only but including
biliary stents and drains). Tiredness symptoms worsened sig-
nificantly in the Intervention Groups 1 (þ 12.0) and 3 (þ 8.8),
with insignificant change in the Intervention Group 2. Pain and
anxiety symptoms improved significantly (change of  11.5 and
 7.9, respectively) in the Intervention Group 2, with no
significant changes in either Intervention Group 1 or 3. Treatment
side effects worsened markedly in the Intervention Group 2
(þ 19.7), with no significant changes in Intervention Groups 1 and
3. Symptoms regarding drains and weight loss did not change
significantly across all three intervention groups between baseline
and follow-up. The worsening of weight loss symptoms (þ 10.0) in
the Intervention Group 3 was not statistically significant, but had a
significant clinical change.
Differences between cholangiocarcinoma and cancer of the
gallbladder. As this module covers more than one group of
diseases clinically, differences between these groups were calcu-
lated. It might be expected that jaundice may be more prominent
in cholangiocarcinoma than gallbladder cancer, but there was no
clear difference in this scale. Mean scores for the QLQ-BIL21 were
calculated at baseline and at follow-up, and any group differences
between cholangiocarcinoma and cancer of the gallbladder were
investigated using repeated-measure ANOVA. Data for the
baseline QLQ-BIL21 are displayed in Table 6. There was a
significant difference between extra- and intrahepatic cholangio-
carcinoma in the drain sites and weight loss questions only, as
might be expected clinically since drains would be used more for
intrahepatic than extrahepatic disease, and weight loss might be
expected if there is a significant bulk of intrahepatic disease. None
of the other scales were significantly different at baseline.
Table 2. Results for test–retest for BIL21 scales
Scale n R2 ICC
ICC for QLQ-BIL21 scales
Eating 67 0.9403 0.875
Jaundice 66 0.9373 0.8665
Tiredness 67 0.9598 0.9157
Pain 66 0.9724 0.9431
Anxiety 67 0.9802 0.9585
Treatment side effects 67 0.9172 0.8268
Drains 66 0.9598 0.9143
Weight loss 67 0.9092 0.8101
Table 3. Construct validity for QLQ-BIL21 questions





































Eating 50.18 32.23 17.98 o0.01
Jaundice 30.19 22.75 7.44 0.139
Tiredness 74.32 52.69 21.62 o0.01
Pain 48.52 33.05 15.46 0.01
Anxiety 63.22 49.25 13.97 0.01
Treatment
side effects
43.65 28.02 15.63 0.05
Drains 28.68 10.32 18.36 0.01
Weight loss 35.51 34.755 0.75 0.898
Abbreviation: KPI¼Karnofsky performance index. Bold indicates non-significance.
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DISCUSSION
The current study is the final stage of a process of development and
validation of a specific set of questions appropriate for biliary tract
cancers. The QLQ-BIL21 questionnaire was conceived as the first
disease-specific QoL assessment tool for patients with cholangio-
carcinoma and cancer of the gall bladder. Although the existing
EORTC questionnaire modules QLQ-PAN26 (Pancreatic Cancer
Module, presently awaiting phase IV validation) (Fitzsimmons
et al, 1999), the QLQ-LMC21 (Colorectal Liver Metastasis module)
(Blazeby et al, 2009) and the FACIT.org questionnaire FACT-Hep
(for all hepatobiliary cancers) covered many similar domains, and
indeed some of their issues contributed to the construction of the
QLQ-BIL21, the differences in presentation and disease course are
reflected in a significantly different scale structure.
This International Phase IV Validation Study of the QLQ-BIL21
questionnaire conducted in accordance with EORTC guidelines
found the reliability and validity of the questionnaire to be robust.
Cronbach’s a-coefficients for all scales overall met the threshold of
40.70. The robustness of the testing parameters indicate that the
QLQ-BIL21 questionnaire will prove clinically useful in trials as
well as in clinical practice. The reliability analysis of the
questionnaire did not fully meet the ideal ICC threshold of
40.90 for all scales (the exceptions being: eating, jaundice,
treatment side effects and weight loss), but exceeded the minimum
reported standard of 0.70. The QLQ-C30 questionnaire behaved
differently in this population, with two scales failing to score an
ICC 40.70. These results are an indication that the QLQ-BIL21
questionnaire may be needed in addition to the QLQ-C30
questionnaire in this patient population.
Analysis of the debriefing questionnaires highlighted that a large
number of patients found QLQ-BIL21 question 50 (‘Have you had
difficulties with drainage tubes/bags) irrelevant. This is not
surprising as not all patients will encounter drains in the course
of their treatment. To maintain clarity, it may therefore be
desirable to enable patients to answer this question and also
question 49 with ‘not applicable’ rather than a Likert scale in the
final version of the questionnaire.
Patients enrolled in India differed statistically from those
in other centres for some characteristics. The Indian cohort of
43 patients was significantly younger with a mean age of 52.24
years, a decade below the next youngest cohort in the Netherlands
(mean age 62.6 years) and over two decades younger than the
oldest cohort in the United Kingdom (Winchester mean age 75.5
years). Furthermore, 93% of Indian patients had primary
gallbladder cancer, compared with an aggregated mean of 21.7%
for all other centres. Overall, 43% of all gallbladder cancer patients
enrolled in the study came from the Indian cohort. Mortality was
also significantly higher in the Indian cohort, with a mortality of
70% (n¼ 30) compared with an overall mortality of 18%, whereas
excluding the Indian patients from the analysis yields an overall
mortality of just 8%. Despite this demographic background, there
seems to be no significant differences in QLQ-BIL21 scores for any
Table 5. Change over time for whole group and intervention subgroups 1–3
Scale/items No. Range of change Mean change s.d. Median Significance P-values
Overall
Eating scale 177  66.67 to 83.33 3.71 24.7 0.0 0.047
Jaundice scale 177 100 to 77.78  7.65 29.0 0.0 0.001
Tiredness scale 178 66.67 to 100 6.05 31.1 0.0 0.01
Pain scale 175 83.33 to 33.33  6.57 21.2 0.0 o0.01
Anxiety scale 176 58.33 to 58.33  3.3 23.5 0.0 0.066
Treatment side effects 170  100 to 100 12.5 38.4 0.0 o0.01
Drains 154  100 to 100  0.43 25.6 0.0 0.834
Weight loss 175  100 to 100 1.71 35.1 0.0 0.519
Scale/items No. Mean change s.d. Median Significance P-values
Intervention Group 1
Eating scale 37 4.28 23.4 0.0 0.281
Jaundice scale 38  13.74 30.2 0.0 0.008
Tiredness scale 37 12.01 30.1 11.1 0.02
Pain scale 38  1.97 23.0 0.0 0.601
Anxiety scale 37  4.28 25.0  8.3 0.304
Treatment side effects 37 4.50 37.8 0.0 0.473
Drains 36 5.56 28.2 0.0 0.245
Weight loss 36 0.93 0.84 0.0 0.845
Intervention Group 2
Eating scale 86 5.23 25.5 8.3 0.06
Jaundice scale 87  5.62 24.0 0.0 0.031
Tiredness scale 87 1.79 31.1 0.0 0.593
Pain scale 85  11.57 21.1  8.3 o0.01
Anxiety scale 85  7.94 20.7  8.3 o0.01
Treatment side effects 81 19.75 37.2 33.3 o0.01
Drains 73  4.57 21.0 0.0 0.068
Weight loss 86  3.10 33.0 0.0 0.386
Intervention Group 3
Eating scale 54 0.93 24.2 0.0 0.78
Jaundice scale 52  6.62 35.1 0.0 0.179
Tiredness scale 54 8.85 31.5 0.0 0.044
Pain scale 52  1.76 18.5 0.0 0.496
Anxiety scale 54 4.78 24.7 8.3 0.161
Treatment side effects 52 7.05 39.2 0.0 0.201
Drains 45 1.48 29.3 0.0 0.736
Weight loss 53 10.06 41.1 0.0 0.081
This shows reduction in jaundice in groups 1 and 2 (due to interventions). In group 2, a reduction in pain and anxiety scores was seen owing to intervention but with an increase in treatment side
effects. Bold indicates non-significance.
BRITISH JOURNAL OF CANCER Quality of life in biliary cancer
1036 www.bjcancer.com |DOI:10.1038/bjc.2016.284
scale, with the exception of jaundice, which is broadly congruent
with clinical expectation.
Known group comparison testing demonstrated the QLQ-BIL21
questionnaire to be adept at identifying group differences at time
points. Of particular interest here was the low correlation between
jaundice and a low KPS. This may be a reflection of the fact that
even a very small tumour load may generate jaundice without a
concurrent effect on systemic symptoms or possibly that jaundice
is often treated at an early stage while the tumour progresses.
Similar results were found in the development of the QLQ-PAN26,
although the jaundice items were retained on expert opinion.
Overall, the measured response to clinical change was not as
marked as anticipated, but was significantly different from baseline
in most scales. This may be a reflection of the short follow-up
period, which was initially selected to prevent patient drop out
owing to clinical deterioration and because it represents the period
of maximal clinical intervention. It would have been desirable to
continue data collection beyond this; however, the poor prognosis
of this rare cancer would have led to a highly significant attrition
rate. Indeed, even at 2 months 50 out of the 263 patients recruited
had died. Comparable studies include a 2010 study of 91 patients
in Romania who were followed up for up to 4 years with regular
QLQ-C30 assessments (Mihalache et al, 2010). At the first
6-month follow-up appointment, statistically significant increases
in global scores were detected. Conversely, a 2015 Thai study of
99 patients found significant decreases in QoL using the FACT-
Hep Questionnaire at 2 months (Woradet et al, 2015). It may
therefore prove desirable to further investigate the QLQ-BIl21
questionnaire in a smaller cohort over a longer time period to
assess response to change over time more thoroughly. When each
group was analysed separately, the changes identified in each
treatment group by the QLQ-BIL21 questionnaire are broadly
congruent with clinical expectation, with less change in Group 3
compared with the other active treatment groups.
Overall, the strengths of this study are that it followed EORTC
module development guidelines, which included many different
languages and cultures, including patients with a wide variety of
stages, therapies and presentations of this disease. A drawback of
this study is that a large proportion of patients were recruited from
the United Kingdom, which may have caused some biases in terms
of language and culture, although it is debatable whether the results
would have been materially different had a more even spread of
international patients been recruited.
Changes to biliary tract cancer therapeutics are evolving.
The first advanced biliary tract cancer randomised phase II trial
(ABC-01) of gemcitabine vs cisplatin/gemcitabine was reported in
2009 (Valle et al, 2009), leading to the pivotal randomised phase III
study (ABC-02) establishing cisplatin/gemcitabine chemotherapy
as the international standard of care regimen for patients with
these disease (Valle et al, 2010). Its sixth iteration (ABC-06),
a phase III randomised controlled trial of oxaliplatin and 5-FU
vs active symptom control in the second-line setting after failure of
cisplatin/gemcitabine chemotherapy, is currently active with
recruitment closing in summer 2016; this study is one of the first
to incorporate the use of QLQ-BIL21. The changes in therapeutics
occurring as a result of these trials may require either a future
adaptation of the QLQ-BIL21 questionnaire to include side effects
of new drugs or an additional module specifically for new
therapies.
CONCLUSION
The QLQ-BIL21 questionnaire has been demonstrated to be a
clinically sensitive, reliable and valid instrument for measuring
QoL in patients with cholangiocarcinoma and cancer of the
gallbladder by this International Multicentre Phase IV Validation
Study. The authors therefore recommend that this tool be used in
the clinical trial and clinical practice setting to provide an accurate
quantification of QoL to guide therapy and future research.
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Table 6. Mean baseline scores for individual sites of disease







Extrahepatic cholangiocarcinoma 78 32.58 27.2
Intrahepatic cholangiocarcinoma 73 32.42 25.6
Gallbladder cancer 87 39.94 28.2
Jaundice scale
Extrahepatic cholangiocarcinoma 78 18.37 25.8
Intrahepatic cholangiocarcinoma 74 25.97 28.2
Gallbladder cancer 85 30.32 31.8
Tiredness scale
Extrahepatic cholangiocarcinoma 78 58.11 31.3
Intrahepatic cholangiocarcinoma 74 55.55 31.4
Gallbladder cancer 83 55.28 31.6
Pain scale
Extrahepatic cholangiocarcinoma 78 30.12 25.0
Intrahepatic cholangiocarcinoma 73 34.36 26.4
Gallbladder cancer 85 42.15 31.8
Anxiety scale
Extrahepatic cholangiocarcinoma 78 52.67 26.6
Intrahepatic cholangiocarcinoma 71 48.98 26.4
Gallbladder cancer 84 52.9 33.3
Treatment side effects
Extrahepatic cholangiocarcinoma 75 31.55 32.4
Intrahepatic cholangiocarcinoma 71 26.76 30.1
Gallbladder cancer 84 35.31 32.3
Drains
Extrahepatic cholangiocarcinoma 73 5.93 17.0
Intrahepatic cholangiocarcinoma 70 13.33 26.0
Gallbladder cancer 82 21.13 33.3
Weight loss
Extrahepatic cholangiocarcinoma 78 25.64 28.4
Intrahepatic cholangiocarcinoma 73 43.83 38.0
Gallbladder cancer 86 34.88 35.0
Bold shows the only significant differences (both P¼ 0.01).
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